Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Research Briefing
  • Published:

Determining the longevity and dynamics of HIV-1 neutralizing activity

The induction of neutralizing antibodies is the main goal of an HIV-1 vaccine, although data on the longevity of such antibodies is lacking. By tracking neutralizing antibodies in a large cohort of individuals infected with HIV-1 who had varying viral loads, we show that the HIV-1 neutralization response can last for several years even at low antigen levels.

This is a preview of subscription content, access via your institution

Access options

Buy this article

Prices may be subject to local taxes which are calculated during checkout

Fig. 1: Durability of HIV-1 neutralization is determined by antigen exposure.


  1. Gruell, H. & Schommers, P. Broadly neutralizing antibodies against HIV-1 and concepts for application. Curr. Opin. Virol. 54, 101211 (2022). This review summarizes the most recent developments in the HIV-1 bNAb field.

    Article  CAS  PubMed  Google Scholar 

  2. Corey, L. et al. Two randomized trials of neutralizing antibodies to prevent HIV-1 acquisition. N. Engl. J. Med. 384, 1003–1014 (2021). This paper reports the results of the Antibody Mediated Protection (AMP) trials.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Haynes, B. F. et al. Strategies for HIV-1 vaccines that induce broadly neutralizing antibodies. Nat. Rev. Immunol. 23, 142–158 (2023). A review that summarizes current efforts in developing bNAb-inducing vaccines.

    Article  CAS  PubMed  Google Scholar 

  4. Landais, E. & Moore, P. Development of broadly neutralizing antibodies in HIV-1 infected elite neutralizers. Retrovirology 15, 61 (2018). An article that reviews our current understanding of the development of neutralizing serum responses in individuals infected with HIV-1.

    Article  PubMed  PubMed Central  Google Scholar 

  5. Schommers, P. et al. Restriction of HIV-1 escape by a highly broad and potent neutralizing antibody. Cell 180, 471–489.e422 (2020). This paper reports the identification of the bNAb 1-18 from elite neutralizer IDC561.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This is a summary of: Schommers, P. et al. Dynamics and durability of HIV-1 neutralization are determined by viral replication. Nat. Med. (2023).

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Determining the longevity and dynamics of HIV-1 neutralizing activity. Nat Med 29, 2720–2721 (2023).

Download citation

  • Published:

  • Issue Date:

  • DOI:


Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing